⚠ DEVELOPMENT ENVIRONMENT — not production
EN
Back to Research Library
Recovery

Tesa

Tesamorelin — stabilized GHRH(1-44) analog

Tesa (Tesamorelin — stabilized GHRH(1-44) analog) research vial
$149.00

At a Glance

Molecular Properties

Molecular FormulaC221H366N72O67S
Molecular Weight5135.9 Da
Sequencetrans-3-hexenoyl-GHRH(1-44) analog (stabilized human GHRH 1-44)

Overview

Compound Description

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone GHRH(1-44), N-terminally modified with a trans-3-hexenoyl group to improve stability relative to the native peptide. In research settings it is studied as a tool for probing the somatotropic (GH/IGF-1) axis, where it acts on the pituitary GHRH receptor. It is characterized as a full-length 44-residue GHRH analog rather than a truncated secretagogue. This profile is provided for research and educational purposes only and is not a description of any therapeutic use.

Mechanism of Action

Research-Identified Pathways

Research indicates that tesamorelin binds the growth-hormone-releasing hormone (GHRH) receptor on pituitary somatotroph cells, a G-protein-coupled receptor whose activation elevates intracellular cyclic AMP and promotes the synthesis and pulsatile secretion of endogenous growth hormone (GH). Because it engages the native GHRH pathway rather than supplying exogenous GH, it is studied as an agent that stimulates the body's own GH output while nominally preserving physiological feedback and pulsatility.

Research further indicates that the defining structural feature is N-terminal stabilization: a trans-3-hexenoyl (hexenoic acid) group attached to the peptide is reported to reduce cleavage by dipeptidyl peptidase-IV (DPP-IV), the enzyme that rapidly degrades native GHRH, thereby extending the analog's functional half-life in circulation. Downstream, GH released in response to receptor activation is understood to drive hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), which is commonly used in research as a marker of somatotropic-axis engagement. These statements describe mechanistic and pharmacological observations only and are not claims of clinical benefit.

Key Research Findings

Published Study Highlights

  • Characterized as a stabilized full-length analog of human GHRH(1-44) bearing an N-terminal trans-3-hexenoyl modification.
  • The N-terminal acyl group is reported to reduce dipeptidyl peptidase-IV (DPP-IV) cleavage, a modification associated with extended plasma half-life relative to native GHRH.
  • Acts as an agonist at the pituitary GHRH receptor, stimulating endogenous growth-hormone synthesis and pulsatile release rather than supplying exogenous GH.
  • Receptor engagement is reported to increase circulating IGF-1, a downstream marker used to index somatotropic-axis activation in research models.
  • Studied in controlled research settings for effects on body composition, notably visceral adipose tissue, without the direct exogenous-GH dosing used in comparison approaches.

Areas of Research Interest

Why Researchers Are Investigating This Compound

This compound has attracted significant research attention in the following areas. These represent active fields of scientific inquiry, not validated therapeutic claims. No medical benefits are stated or implied.

  • Somatotropic-axis pharmacology: GHRH-receptor agonism and its effect on endogenous GH secretion and downstream IGF-1 as an axis readout.
  • Peptide stabilization chemistry: how N-terminal acylation and DPP-IV resistance alter half-life and pharmacokinetics versus native GHRH.
  • Metabolic and visceral-adipose research models: investigation of GHRH-analog exposure on adipose-tissue distribution in controlled study populations.
  • Endocrine-pharmacology comparison: contrasting secretagogue-driven endogenous GH release with direct exogenous GH administration in research designs.

Published Research

Peer-Reviewed References

  1. Falutz J, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine (2007). doi:10.1056/NEJMoa072375
  2. Falutz J, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data." The Journal of Clinical Endocrinology & Metabolism (2010). doi:10.1210/jc.2010-0490
  3. Makimura H, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Obese Subjects with Reduced Growth Hormone Secretion: A Randomized Controlled Trial." The Journal of Clinical Endocrinology & Metabolism (2012). doi:10.1210/jc.2012-2794
  4. Stanley TL, et al. "Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial." JAMA (2014). doi:10.1001/jama.2014.8334

Research Use Only

The information presented on this page is compiled from peer-reviewed scientific literature and is provided solely for educational and research purposes. This compound is intended exclusively for laboratory and scientific research use. It is not a drug, pharmaceutical, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. No claims of therapeutic efficacy are made or implied.

Researchers are advised to consult the original published studies referenced above for complete methodological details, study limitations, and the authors' own conclusions. Atlas Peptide Research does not endorse any specific research application and provides this information as a reference resource only.

Interested in Tesa?

View this compound in our shop to see available sizes, certificates of analysis, and current pricing.

View in Shop
For research use only. Not for human consumption. Products are intended solely for laboratory and scientific research purposes.